Head-to-head · free
Moderna vs NanoViricides, Inc.
MRNA vs NNVC — return on capital, cash generation, margins and balance sheet side by side.
MRNA
0 / 2
measures where MRNA leads
NNVC
2 / 2
measures where NNVC leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MRNA · FY2025 | NNVC · FY2026 |
|---|---|---|
| Revenue | $1.9B | — |
| Net income | (2.8B) | (8.2M) |
| Revenue growth (yearly, multi-year) | -43.0% | — |
| Free cash flow | (2.1B) | (7.8M) |
| Free cash flow margin | -106.2% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -28.9% | — |
| Gross margin | 54.8% | — |
| Operating margin | -159.9% | — |
| Net debt / EBITDA | 0.70x | — |
Figures are as reported by each company; latest fiscal year shown.
Where Moderna's cash went (FY2025)
- Capital spending
- $192.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where NanoViricides, Inc.'s cash went (FY2026)
- Capital spending
- $84317
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free